Background
Rhabdomyosarcoma (RMS) is among the most common soft tissue sarcomas in childhood and adolescence with 4.5 new cases/1 million person/year in the USA and incidences in Europe share similar numbers [
1,
2]. It is a high-grade malignancy that primarily involves the head and neck region, the urogenital tract or may develop in soft tissues of the trunk or extremities. Histologically, RMS is comprised of four subtypes; among which embryonal and alveolar RMSs are the most common ones under the age of 20, while pleomorphic and spindle cell variants of the tumor may also occur in adults, with a peak at the 4th-5th and 6th -7th decades of lifetime, respectively. RMS is a high-grade malignancy and the subtype determines the prognosis of the disease. While embryonal RMS has a better outcome (5-year survival rate of 82 %), the alveolar variant of the tumor has a worse prognosis (5-year survival rate of 65 %) which is presumably associated with the cytogenetic aberrations this latter subtype carry [
3,
4]. Alveolar RMS can be characterized by a recurrent cytogenetic alteration involving FOXO-1 and PAX3 or PAX7 genes, and the consecutive translocations (t(2;13) or t(1;13) respectively) lead to the excess synthesis of fusion proteins with oncogenic effects [
5,
6].
Available data about primary bone ARMS is limited due to the fact that so far only four cases were found in literature reporting fusion-positive alveolar RMS confined to the bone marrow [
7‐
10]. Thus, it is difficult to predict the disease course, the biological behavior and its characteristics. Nonetheless, according to these reports as well as our experiences, primary bone ARMS seems to have a better prognosis and survival rate compared to its soft tissue counterpart. Here we report two further cases of primary ARMS of the bone that posed a diagnostic challenge both from a clinical as well as a pathological point of view.
Discussion
Alveolar rhabdomyosarcoma is a high grade neoplasm that has the worst prognosis amongst other subtypes of RMSs (despite combined surgical and chemo/radiotherapy), especially in fusion-positive cases when FOXO-1 gene is involved. It is generally known that the overall outcomes for patients with soft tissue ARMS is worse than in patients with ERMS - even with aggressive multimodal therapy [
4]. The prognostic factors defining the outcome of patients with RMS includes the following parameters: patient’s age, site of origin, tumor size, resectability, presence of metastases, number of metastatic sites or tissues involved, presence or absence of regional lymph node involvement, delivery of radiation therapy in selected cases, the unique biological characteristics of RMS tumor cells and, lastly the histological subtype. [
11‐
14]. Regarding the histopathological subtype, there is a significant difference between the 5-year survival with ERMS (82 %) and soft tissue ARMS (65 %) [
4]. Besides this, patients with (soft tissue) ARMS who have regional lymph node involvement face a worse outcome (5-year failure-free survival: 43 %) as compared to patients lacking lymph node involvement (5-year failure-free survival: 73 %) [
15].
Although the previously reported four cases of primary ARMS (as well as our current two cases) show a better survival rate compared to its soft tissue counterpart, it still causes difficulties in precisely characterizing this tumor type. One reason is the low number of reported cases, while a major problem alongside this is that even data contained within medical literature is confusing with regards to ARMS classification. It distinguishes fusion-positive and fusion-negative cases; however, there is a tendency that fusion-negative cases should be considered in practical terms ERMS [
16]. Until this tendency is not generalized and accepted in routine diagnostic pathology, there will be cases influencing and altering the results exhibited in statistics.
In the case of (soft tissue) alveolar RMS it is known that it commonly infiltrates the bone marrow [
17], causing a diagnostic challenge (both in childhood and adult cases), as it can mimic the symptoms of either a hematological malignancy or a primary bone tumor; therefore, biopsy sampling is necessary in each and every case. The most common differential diagnostic problems (considering the localization and/or age) are as follows: Ewing sarcoma, non-Hodgkin lymphoma, mesenchymal chondrosarcoma and the small cell variant of osteosarcoma. While the morphology of tumor cells are similar (small, round cells), the pattern of infiltration or the accompanying component of the tumor (neoplastic osteoid or hyaline cartilage in small cell variant of OS and mesenchymal chondrosarcoma, respectively) as well as special cytomorphological features such as intracytoplasmic vacuoles or striation of the tumor cells (like in RMS) may sometimes suggest the differentiation lineage. Besides the careful examination of HE stained samples and morphological analysis, ancillary techniques are essential in these cases in order to give a definitive diagnosis. The combination of IHC tests including LCA, vimentin, desmin and CD99 is useful to primarily assess the phenotype of the tumor cells. Although IHC evaluation is sufficient and may lead to a final diagnosis, in most of the cases further molecular examinations such as flow cytometry (especially in hematological diseases) or genetic analysis with regard to gene fusion status (e.g. in Ewing sarcoma and ARMS) are now part of the routine diagnostic panel [
18,
19].
The natural history of primary alveolar RMS of bone may show individual variations, but our current cases, together with the other four reported ones [
7‐
10], suggest a better overall prognosis as compared to soft tissue ARMS (Table
1). Primary alveolar rhabdomyosarcoma of the bone as a subtype of ARMS seems to be a distinct clinico-pathological entity. We wish to stimulate the scientific community into publishing and following-up similar cases. With this proposal, there might be more available data to predict not only the biological behavior and prognosis of the disease, but also to develop and set up further chemotherapeutical combinations that may increase the overall survival of the patients in the future.
Table 1
Reported cases of primary alveolar rhabdomyosarcoma of the bone so far without identifiable soft tissue component
1 | Yamaguchi et al. 2007 [ 9] | 14 | m | 8 (s) | -Etoposide | Disseminated BM infiltration, not specified |
-Cyclophosphamide |
-Pirarubicin |
-Cisplatin |
-Vincristine |
2 | | 16 | m | 8 (s) | -VP16 | Disseminated BM infiltration, not specified |
-Ifosfamide |
-Vincristine |
-Adriamycin |
-Cyclophosphamide |
3 | | 52 | f | 12 (s) | Not detailed | BM infiltration, not specified |
4 | Karagiannis et al. (2015) [ 8] | 61 | f | 7 (f) | -Topotecan | BM infiltration, not specified |
-Cyclophosphamide |
-Vinorelbine (Monotherapy-later) |
5 | Case 1 (current report) | 17 | m | 7 (s) | -Ifosfamid | Diffuse BM infiltration |
-Carboplatin |
-Etoposid |
-Vincristin |
6 | Case 2 (current report) | 9 | m | 30 (s) | -Ifosfamid | Tibia, femur, pelvic bones, vertebrae |
-Etoposid |
-Carboplatin |
-Topotecan |
Conclusion
Primary alveolar rhabdomyosarcoma of the bone as a subtype of ARMS, seems to be a distinct clinico-pathological entity with challenging diagnostic difficulties and different biological behavior when compared to soft tissue ARMS. More available data might be necessary to predict not only the course of the disease, but also to develop and set up further chemotherapeutical combinations that may increase the overall survival of the patients in the future.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.